Using the PARI Filter Valve Set with the eFlow®rapid nebuliser handset Cleaning the eFlow®rapid aerosol head with the easycare cleaning aid Please note: When you click on a link, you leave our homepage and open a YouTube page. For more information, please see our Privacy Policy. This...
The eFlow®rapidnebuliser handset is intended to be used in combination with an eFlow®rapidcontrol unit (type 178) or an eBase®Controller (type 678). Nebuliser solutions or suspensions, which are approved for the treatment of diseases of the lower airways can be administered as an aerosol...
The current study identified the impact of formulation variables on the aerosolization performance of the eFlowrapid with special respect to optimized lung application. API formulations (including excipient-supplemented samples) were investigated for physicochemical properties, then nebulized using vibrating-...
167 Inhalation with PARI eFlow® rapid reduces treatment burden significantly in adult CF patients without altering lung functiondoi:10.1016/S1569-1993(07)60153-2R.FischerandS.NaehrigandM.KerscherandR.M.SDOSJournal of Cystic Fibrosis
50 Pharmacokinetic comparison of inhaled tobramycin (TOBI®) via PARI eFlow® rapid or PARI LC Plus™ nebulizers in cystic fibrosis patients - Journal of Cystic Fibrosisdoi:10.1016/S1569-1993(07)60043-5D. HubertS. LeroyS. Dominique
To the Editor: I refer to the article with the title "Changes in Performance of the PARI eFlow[R] Rapid and PARI LC Plus[TM] during 6 Months Use by CF Patients" published in September 2009 by Rottier et al. in the Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 22...
Naehrig S, Lang S, Schiffl H, Huber RM, Fischer R: Lung function in adult patients with cystic fibrosis after using the eFlow rapid for one year. Eur J Med Res 2011, 16:63-66.Naehrig S, Lang S, Schiffl H, Huber RM, Fischer R. Lung function in adult patients with cystic fibrosis ...
Rottier BL, van Erp CJ, Sluyter TS, Heijerman HGM, Frijlink HW, de Boer AH (2009) Changes in performance of the pari eFlow rapid and pari LC plus during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv 22(3):263–269...
I am somewhat disturbed by the methodology in the recent publication by Rottier et al. discussing the performance of the PARI eFlow Rapid and the PARI LC Plus. For example, they used laser diffraction with the Fraunhofer theory for particle sizing and found the differences between their results ...
A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eFlow Rapid Nebulizer System in Patients With Cystic FibrosisGenentechBone & Cancer Foundation